XTANT MEDICAL HOLDINGS INC (XTNT) Stock Price & Overview

NYSEARCA:XTNT • US98420P3082

Current stock price

0.621 USD
+0.02 (+2.87%)
Last:

The current stock price of XTNT is 0.621 USD. Today XTNT is up by 2.87%. In the past month the price increased by 6.46%. In the past year, price increased by 29.38%.

XTNT Key Statistics

52-Week Range0.3401 - 0.95
Current XTNT stock price positioned within its 52-week range.
1-Month Range0.55 - 0.705
Current XTNT stock price positioned within its 1-month range.
Market Cap
86.94M
P/E
62.10
Fwd P/E
121.76
EPS (TTM)
0.01
Dividend Yield
N/A

XTNT Stock Performance

Today
+2.87%
1 Week
+0.16%
1 Month
+6.46%
3 Months
-14.34%
Longer-term
6 Months -1.58%
1 Year +29.38%
2 Years -46.92%
3 Years -2.59%
5 Years -73.69%
10 Years -77.08%

XTNT Stock Chart

XTANT MEDICAL HOLDINGS INC / XTNT Daily stock chart

XTNT Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to XTNT. When comparing the yearly performance of all stocks, XTNT turns out to be only a medium performer in the overall market: it outperformed 66.5% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

XTNT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to XTNT. Both the profitability and financial health of XTNT have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

XTNT Earnings

On November 10, 2025 XTNT reported an EPS of 0.01 and a revenue of 33.26M. The company beat EPS expectations (296.08% surprise) and missed revenue expectations (-0.3% surprise).

Next Earnings DateMar 20, 2026
Last Earnings DateNov 10, 2025
PeriodQ3 / 2025
EPS Reported$0.01
Revenue Reported33.255M
EPS Surprise 296.08%
Revenue Surprise -0.30%

XTNT Forecast & Estimates

8 analysts have analysed XTNT and the average price target is 1.53 USD. This implies a price increase of 146.38% is expected in the next year compared to the current price of 0.621.

For the next year, analysts expect an EPS growth of 121.25% and a revenue growth 12.6% for XTNT


Analysts
Analysts85
Price Target1.53 (146.38%)
EPS Next Y121.25%
Revenue Next Year12.6%

XTNT Groups

Sector & Classification

Index Membership

XTNT Financial Highlights

Over the last trailing twelve months XTNT reported a non-GAAP Earnings per Share(EPS) of 0.01. The EPS increased by 107.69% compared to the year before.


Income Statements
Revenue(TTM)117.27M
Net Income(TTM)-4.58M
Industry RankSector Rank
PM (TTM) N/A
ROA -4.43%
ROE -9.44%
Debt/Equity 0.46
Chartmill High Growth Momentum
EPS Q2Q%125%
Sales Q2Q%19.04%
EPS 1Y (TTM)107.69%
Revenue 1Y (TTM)28.44%

XTNT Ownership

Ownership
Inst Owners57.97%
Shares140.00M
Float118.75M
Ins Owners15.18%
Short Float %0.02%
Short Ratio0.15

XTNT Competitors/Peers

The largest stocks on the US markets in the "Health Care Supplies" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
MDLN MEDLINE INC-CL A27.7854.466B
COO COOPER COS INC/THE13.9813.642B
ALGN ALIGN TECHNOLOGY INC14.2711.706B
SOLV SOLVENTUM CORP10.1611.582B
LNTH LANTHEUS HOLDINGS INC14.725.136B
MMSI MERIT MEDICAL SYSTEMS INC16.884.157B
ICUI ICU MEDICAL INC15.213.107B
HAE HAEMONETICS CORP/MASS11.152.784B
XRAY DENTSPLY SIRONA INC7.872.305B
NEOG NEOGEN CORP26.81.977B
UFPT UFP TECHNOLOGIES INC201.572B
STAA STAAR SURGICAL CO133.29937.102M
BVS BIOVENTUS INC - A11.04713.391M

About XTNT

Company Profile

XTNT logo image Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The company is headquartered in Belgrade Montana, Montana and currently employs 217 full-time employees. The company went IPO on 2010-06-30. The firm is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoVive, OsteoFactor, line of 3Demin products, as well as other allografts. The company offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical products, Thoracolumbar products, Sacroiliac Joint products, and Interbody products.

Company Info

IPO: 2010-06-30

XTANT MEDICAL HOLDINGS INC

664 Cruiser Lane

Belgrade Montana MONTANA 59714 US

CEO: Sean E. Browne

Employees: 217

XTNT Company Website

XTNT Investor Relations

Phone: 14063880480

XTANT MEDICAL HOLDINGS INC / XTNT FAQ

Can you describe the business of XTANT MEDICAL HOLDINGS INC?

Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The company is headquartered in Belgrade Montana, Montana and currently employs 217 full-time employees. The company went IPO on 2010-06-30. The firm is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoVive, OsteoFactor, line of 3Demin products, as well as other allografts. The company offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical products, Thoracolumbar products, Sacroiliac Joint products, and Interbody products.


What is the current price of XTNT stock?

The current stock price of XTNT is 0.621 USD. The price increased by 2.87% in the last trading session.


Does XTANT MEDICAL HOLDINGS INC pay dividends?

XTNT does not pay a dividend.


What is the ChartMill rating of XTANT MEDICAL HOLDINGS INC stock?

XTNT has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


How is the valuation of XTANT MEDICAL HOLDINGS INC (XTNT) based on its PE ratio?

The PE ratio for XTANT MEDICAL HOLDINGS INC (XTNT) is 62.1. This is based on the reported non-GAAP earnings per share of 0.01 and the current share price of 0.621 USD.


Can you provide the number of employees for XTANT MEDICAL HOLDINGS INC?

XTANT MEDICAL HOLDINGS INC (XTNT) currently has 217 employees.